REMD is a biopharmaceutical company focused on discovering and developing cutting-edge bio-medicines to treat cancer, diabetes and other diseases. The firm is organized around developing world class, high quality,and efficient medicine by uniting top American medical scientists and elite Chinese pharmaceutical assets, leveraging the world's most advanced research and development technologies. Currently, REMD, Inc conducts clinical studies of the therapeutic antibody, REMD-477, for the treatment of type 1 and 2 diabetes. As an example - One of Amgenâs shelved projects, AMG-477 found new life when REMD in-licensed the drug on May 2013. The drug was subsequently renamed REMD-477 and the REMD team continued research where Amgen had left off. REMD-477 was once placed on a full clinical hold when an initial Amgen study found pancreatic fibrosis in some older male rats. The REMD team successfully convinced the FDA that this observation was not causally related to REMD-477. On October 2013, the FDA lifted the hold, agreeing that âthe pancreatic fibrotic lesionsâ¦are spontaneous, age-related lesions,â and thus were not a clinical safety concern. REMDâs ensuing findings were so meaningful, that they published their first paper on Type 1 Diabetes Mellitus in the Proceedings of the National Academy of Sciences (PNAS) on February 24, 2015. The paper showed significant evidence of hyperglycemia correction, several metabolic marker improvements, and restoration of normal HbA1c levels, after treatment using REMD-477 or its analogues in a number of type 1 diabetic models in mice. Clinical trials have been undrtaken in type II diabetic patients at three sites in California, Texas, and
